NCT07198009

Brief Summary

The goal of this clinical trial is to learn if a natural supplement called 2-hydroxybenzylamine (2-HOBA) can reduce harmful oxidized lipids and improve the function of lipoprotein(a) in adults with high lipoprotein(a) levels. The main questions it aims to answer are: Does 2-HOBA lower oxidized phospholipids on lipoprotein(a)? Does 2-HOBA reduce markers of inflammation and blood clotting in the blood? Participants will: Take 2-HOBA capsules (400 mg, three times daily with meals) for 6 weeks Provide blood and urine samples at the beginning, middle, and end of the study Have lab tests to measure changes in lipids, inflammation, and clotting markers

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
6mo left

Started Nov 2025

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress52%
Nov 2025Nov 2026

First Submitted

Initial submission to the registry

September 25, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 30, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

November 1, 2025

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2026

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2026

Expected
Last Updated

September 30, 2025

Status Verified

September 1, 2025

Enrollment Period

4 months

First QC Date

September 25, 2025

Last Update Submit

September 25, 2025

Conditions

HyperlipidemiaElevated Lp(a)

Keywords

Oxidized Phospholipidslp(a)2HOBA

Outcome Measures

Primary Outcomes (1)

  • Change in oxidized phospholipids (OxPL) on circulating lipoprotein(a)

    OxPL levels on circulating lipoprotein(a) will be measured in blood samples collected before and after 6 weeks of oral 2-HOBA supplementation.

    6 weeks

Secondary Outcomes (8)

  • High-sensitivity CRP

    6 weeks

  • Interleukin-6

    6 weeks

  • Tumor Necrosis Factor-alpha (TNF-α)

    6 weeks

  • Fibrinogen

    6 weeks

  • D-dimer

    6 weeks

  • +3 more secondary outcomes

Study Arms (1)

2-HOBA Supplementation for Elevated Lipoprotein(a)

EXPERIMENTAL

Participants will take oral 2-hydroxybenzylamine (2-HOBA, Hobamine) at a dose of 400 mg three times daily with meals for 6 weeks.

Dietary Supplement: 2-HOBA (Hobamine)

Interventions

2-HOBA (Hobamine)DIETARY_SUPPLEMENT

Participants will take oral 2-hydroxybenzylamine (2-HOBA, Hobamine), a dietary supplement with Generally Recognized as Safe (GRAS) status. The study dose is 400 mg three times daily with meals for 6 weeks.

2-HOBA Supplementation for Elevated Lipoprotein(a)

Eligibility Criteria

Age18 Years - 69 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males and females aged 18-69 years.
  • Elevated Lp(a) levels ≥ 90 mg/dL.
  • Able to provide informed consent and adhere to study schedules.
  • Willing to follow a physician-recommended diet during the study.

You may not qualify if:

  • Pregnant, planning pregnancy during the study period, or currently breastfeeding.
  • Individuals with established cardiovascular disease
  • Planning major changes in diet or exercise routines.
  • Experienced \>20% weight change in the past 3 months.
  • Diagnosed with malabsorption syndrome or chronic diarrhea.
  • Abnormal liver, kidney, or thyroid function.
  • Drug or alcohol abuse within the past 6 months, or significant mental/psychological impairment.
  • Have known bleeding disorders (e.g., hemophilia).
  • Planned surgery during the study period.
  • Donated blood within the last 2 weeks or planning to donate during the study.
  • Require regular blood transfusions.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lipid Clinic at Brown University Health

Providence, Rhode Island, 02914, United States

Location

MeSH Terms

Conditions

Hyperlipidemias

Interventions

2-(aminomethyl)phenol

Condition Hierarchy (Ancestors)

DyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Wenliang Song, MD

    The Miriam Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Wenliang Song, MD

CONTACT

4014449851wsong@brownhealth.org

Daria Salamevich

CONTACT

4014449857dsalamevich@brownhealth.org

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 25, 2025

First Posted

September 30, 2025

Study Start

November 1, 2025

Primary Completion

March 1, 2026

Study Completion (Estimated)

November 1, 2026

Last Updated

September 30, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations

US(1)